Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
type
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1145510

	registered interest
	date	24/09/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	National Institute for Health and Care Excellence
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will publish the roles of the members of the (a) steering group, (b) working group and (c) each of the task and finish groups for NICE's review into its methods and processes.
	tabling member constituency	Scunthorpe
	tabling member printed	Nic Dakin
	type	WrittenParliamentaryQuestion
	uin	290336
	answer	answer is ministerial correction date of answer 30/09/2019 answer text <p>The steering group and working group members and their roles are published on the National Institute for Health and Care Excellence (NICE) website at the following link:</p><p><a href="https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/changes-to-health-technology-evaluation" target="_blank">https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/changes-to-health-technology-evaluation</a></p><p>NICE has advised the Department that it plans to publish the names of those people involved in the task and finish groups on its website as soon as they are confirmed.</p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 30/09/2019 17:05:30 answering member 4380 label Biography information for Jo Churchill
	tabling member	4056 label Biography information for Nic Dakin

1175547

	registered interest
	date	03/02/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	National Institute for Health and Care Excellence
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, which patient organisations are members of the (a) modifiers considered in decision-making, (b) exploring uncertainty, (c) types of evidence, (d) health-related quality of life, (e) technology specific issues, (f) discounting, (g) cost-minimisation methods (h) costs used in HTA, (i) equality considerations in guideline development, (j) general approach to decision-making and (k) position of technologies in care pathway, NICE methods review task and finish groups.
	tabling member constituency	Sheffield South East
	tabling member printed	Mr Clive Betts
	type	WrittenParliamentaryQuestion
	uin	11443
	answer	answer is ministerial correction date of answer 06/02/2020 answer text <p>The following patient groups are currently involved across the programme of task and finish groups. The National Institute for Health and Care Excellence (NICE) has advised that it continues to seek further members for the task and finish groups, and a full list of members is still to be finalised.</p><p>- Alzheimer's Research UK;</p><p>- Breast Cancer Now;</p><p>- Cancer52;</p><p>- Cystic Fibrosis Trust ;</p><p>- Diabetes UK;</p><p>- Genetic Alliance UK;</p><p>- Leukaemia CARE;</p><p>- Multiple Sclerosis Society;</p><p>- Muscular Dystrophy UK;</p><p>- Myeloma UK;</p><p>- Neuroendocrine Cancer UK;</p><p>- Prostate cancer UK; and</p><p>- Sarcoma UK.</p><p> </p><p>In recruiting patient organisations to the NICE methods review task and finish groups, patients on the methods working group were asked to nominate representatives with a range of experience. Additional representatives were nominated by NICE where particular expertise or input was required. The organisations involved in the task and finish groups cover a broad spectrum of disease areas including cancer, non-cancer and rare diseases.<strong> </strong></p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 11444 question first answered 06/02/2020 17:20:14 answering member 4380 label Biography information for Jo Churchill
	tabling member	394 label Biography information for Mr Clive Betts

1175548

	registered interest
	date	03/02/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	National Institute for Health and Care Excellence
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how patient organisations were recruited to the 11 NICE methods review task and finish groups.
	tabling member constituency	Sheffield South East
	tabling member printed	Mr Clive Betts
	type	WrittenParliamentaryQuestion
	uin	11444
	answer	answer is ministerial correction date of answer 06/02/2020 answer text <p>The following patient groups are currently involved across the programme of task and finish groups. The National Institute for Health and Care Excellence (NICE) has advised that it continues to seek further members for the task and finish groups, and a full list of members is still to be finalised.</p><p>- Alzheimer's Research UK;</p><p>- Breast Cancer Now;</p><p>- Cancer52;</p><p>- Cystic Fibrosis Trust ;</p><p>- Diabetes UK;</p><p>- Genetic Alliance UK;</p><p>- Leukaemia CARE;</p><p>- Multiple Sclerosis Society;</p><p>- Muscular Dystrophy UK;</p><p>- Myeloma UK;</p><p>- Neuroendocrine Cancer UK;</p><p>- Prostate cancer UK; and</p><p>- Sarcoma UK.</p><p> </p><p>In recruiting patient organisations to the NICE methods review task and finish groups, patients on the methods working group were asked to nominate representatives with a range of experience. Additional representatives were nominated by NICE where particular expertise or input was required. The organisations involved in the task and finish groups cover a broad spectrum of disease areas including cancer, non-cancer and rare diseases.<strong> </strong></p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 11443 question first answered 06/02/2020 17:20:14 answering member 4380 label Biography information for Jo Churchill
	tabling member	394 label Biography information for Mr Clive Betts

1175549

	registered interest
	date	03/02/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	National Institute for Health and Care Excellence
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps the NICE methods review task and finish groups will take to consult with the wider health charity sector.
	tabling member constituency	Sheffield South East
	tabling member printed	Mr Clive Betts
	type	WrittenParliamentaryQuestion
	uin	11445
	answer	answer is ministerial correction date of answer 06/02/2020 answer text <p>The National Institute for Heath and Care Excellence (NICE) has advised that a six week public consultation on the proposals for changing its methods and processes will take place this summer. We understand that further work on the timetable is in progress and will be communicated in due course.</p><p>The wider health charity sector will have an opportunity to review the proposals for change from the task and finish groups during this consultation.</p><p>NICE also held a webinar with stakeholders in November 2019 to share how and why health technology evaluation is changing and what it means for patients. The webinar is available on the NICE website at the following link:</p><p><a href="https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/changes-to-health-technology-evaluation" target="_blank">https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/changes-to-health-technology-evaluation</a></p><p>NICE staff have also participated in a number of events to engage with the patient community, including the charity sector and about the methods review.</p><p><strong> </strong></p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 11446 question first answered 06/02/2020 17:21:30 answering member 4380 label Biography information for Jo Churchill
	tabling member	394 label Biography information for Mr Clive Betts

1175550

	registered interest
	date	03/02/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	National Institute for Health and Care Excellence
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what the timetable is for the publication of the full consultation on the proposed reforms to NICE methods and processes.
	tabling member constituency	Sheffield South East
	tabling member printed	Mr Clive Betts
	type	WrittenParliamentaryQuestion
	uin	11446
	answer	answer is ministerial correction date of answer 06/02/2020 answer text <p>The National Institute for Heath and Care Excellence (NICE) has advised that a six week public consultation on the proposals for changing its methods and processes will take place this summer. We understand that further work on the timetable is in progress and will be communicated in due course.</p><p>The wider health charity sector will have an opportunity to review the proposals for change from the task and finish groups during this consultation.</p><p>NICE also held a webinar with stakeholders in November 2019 to share how and why health technology evaluation is changing and what it means for patients. The webinar is available on the NICE website at the following link:</p><p><a href="https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/changes-to-health-technology-evaluation" target="_blank">https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/changes-to-health-technology-evaluation</a></p><p>NICE staff have also participated in a number of events to engage with the patient community, including the charity sector and about the methods review.</p><p><strong> </strong></p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 11445 question first answered 06/02/2020 17:21:30 answering member 4380 label Biography information for Jo Churchill
	tabling member	394 label Biography information for Mr Clive Betts

1186534

	registered interest
	date	19/03/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	National Institute for Health and Care Excellence
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will support the National Institute for Health and Care Excellence to undertake its methods and processes in a way that (a) enables the attractiveness of the UK as a place to conduct clinical trials or supply human medicines and (b) enables that organisation to fulfil its statutory duty to promote innovation.
	tabling member constituency	Reigate
	tabling member printed	Crispin Blunt
	type	WrittenParliamentaryQuestion
	uin	32039
	answer	answer is ministerial correction date of answer 29/05/2020 answer text <p>The National Institute for Health and Care Excellence (NICE) is reviewing its methods for the development of technology appraisal and highly specialised technology recommendations in line with the commitment in the 2019 voluntary scheme for branded medicines pricing and access. The scheme also states the Government’s expectations for the review as follows: ‘“The Department expects that any future changes to NICE methods and processes would respond to the new types of innovation coming to the market, be consistent with improving the health gain achieved by spending on new innovative medicines, and support faster adoption of the most clinically and cost effective medicines.”’</p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 32038 question first answered 29/05/2020 16:49:06 answering member 4380 label Biography information for Jo Churchill
	tabling member	104 label Biography information for Crispin Blunt

1399150

	registered interest
	date	04/01/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	National Institute for Health and Care Excellence
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what discussions his Department has had with NICE on their (a) current and (b) future capacity to deliver final draft guidance on medicines within three months of regulatory approval by the MHRA.
	tabling member constituency	Bolton West
	tabling member printed	Chris Green
	type	WrittenParliamentaryQuestion
	uin	96908
	answer	answer is ministerial correction date of answer 11/01/2022 answer text <p>The National Institute for Health and Care Excellence (NICE) is committed to publishing draft recommendations on new medicines around the time of licensing, with final guidance within three months of licensing wherever possible. The Department holds regular accountability meetings with NICE on a range of topics, including capacity issues. NICE delivers timely guidance on new medicines in the vast majority of cases and expects to continue to do so.</p><p>Project Orbis has been established to allow participating partners, including the United Kingdom, to review and approve applications for promising cancer treatments efficiently. The Medicines and Healthcare products Regulatory Agency, NICE and NHS England and NHS Improvement are ensuring an integrated, timely approach to access new products, including those licensed through Project Orbis. NHS England and NHS Improvement and NICE have agreed principles to allow potential interim access ahead of NICE’s guidance where timely guidance is not anticipated, which has supported early patient access for a number of medicines licensed through Project Orbis.</p> answering member constituency Charnwood answering member printed Edward Argar grouped question UIN 96909 96910 question first answered 11/01/2022 09:29:32 answering member 4362 label Biography information for Edward Argar
	tabling member	4398 label Biography information for Chris Green

1399156

	registered interest
	date	04/01/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	National Institute for Health and Care Excellence
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the impact of operational challenges faced by NICE on its ability to deliver timely patient access to new medicines.
	tabling member constituency	Bolton West
	tabling member printed	Chris Green
	type	WrittenParliamentaryQuestion
	uin	96910
	answer	answer is ministerial correction date of answer 11/01/2022 answer text <p>The National Institute for Health and Care Excellence (NICE) is committed to publishing draft recommendations on new medicines around the time of licensing, with final guidance within three months of licensing wherever possible. The Department holds regular accountability meetings with NICE on a range of topics, including capacity issues. NICE delivers timely guidance on new medicines in the vast majority of cases and expects to continue to do so.</p><p>Project Orbis has been established to allow participating partners, including the United Kingdom, to review and approve applications for promising cancer treatments efficiently. The Medicines and Healthcare products Regulatory Agency, NICE and NHS England and NHS Improvement are ensuring an integrated, timely approach to access new products, including those licensed through Project Orbis. NHS England and NHS Improvement and NICE have agreed principles to allow potential interim access ahead of NICE’s guidance where timely guidance is not anticipated, which has supported early patient access for a number of medicines licensed through Project Orbis.</p> answering member constituency Charnwood answering member printed Edward Argar grouped question UIN 96908 96909 question first answered 11/01/2022 09:29:32 answering member 4362 label Biography information for Edward Argar
	tabling member	4398 label Biography information for Chris Green

1271496

	registered interest
	date	15/12/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	National Institute for Health and Care Excellence
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the level of patient involvement in the NICE process for evaluating and approving new medicines and treatment; and whether there are plans under the ongoing Methods Review to adjust that level of involvement.
	tabling member constituency	Nottingham North
	tabling member printed	Alex Norris
	type	WrittenParliamentaryQuestion
	uin	130207
	answer	answer is ministerial correction date of answer 27/01/2021 answer text <p>The National Institute for Health and Care Excellence (NICE) is an independent body and is therefore responsible for its own methods and processes for evaluations and approving new medicines and treatments. Consultee organisations for NICE’s technology appraisals include national groups representing patients and carers.</p><p>NICE has had patient involvement throughout its methods and process review, including a specific workstream led by patient representatives and senior NICE staff. Patient groups are also represented on its Methods Review Working Group.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 27/01/2021 15:29:38 answering member 4380 label Biography information for Jo Churchill previous answer version 72723 answering member constituency Bury St Edmunds answering member printed Jo Churchill answering member 4380 label Biography information for Jo Churchill
	tabling member	4641 label Biography information for Alex Norris

1204449

	registered interest
	date	16/06/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	National Institute for Health and Care Excellence
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve the methodology used by NICE to appraise combination therapies in the ongoing NICE Methods Review.
	tabling member constituency	Nottingham North
	tabling member printed	Alex Norris
	type	WrittenParliamentaryQuestion
	uin	59876
	answer	answer is ministerial correction date of answer 07/07/2020 answer text <p>The National Institute for Health and Care Excellence (NICE) is an independent body and is responsible for the methods it uses in developing its guidance. While NICE is currently undertaking a review of its methods for health technology evaluation, the review is not considering combination treatments as a specific topic.</p><p>Commercial and policy-related challenges for combination treatments are being explored in other projects in line with the commitments in the Voluntary Scheme for Branded Medicines Pricing and Access. As stated in the Scheme, the Department and NHS England and NHS Improvement will support the Association of the British Pharmaceutical Industry’s efforts to find solutions to these challenges.</p><p> </p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 07/07/2020 15:03:10 answering member 4380 label Biography information for Jo Churchill previous answer version 31043 answering member constituency Bury St Edmunds answering member printed Jo Churchill answering member 4380 label Biography information for Jo Churchill
	tabling member	4641 label Biography information for Alex Norris